Adherence with tobramycin inhaled solution and health care utilization

Becky A. Briesacher, Alexandra Quittner, Lisa Saiman, Patricia Sacco, Hassan Fouayzi, Lynne M. Quittell

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Background: Adherence with tobramycin inhalation solution (TIS) during routine cystic fibrosis (CF) care may differ from recommended guidelines and affect health care utilization.Methods: We analyzed 2001-2006 healthcare claims data from 45 large employers. Study subjects had diagnoses of CF and at least 1 prescription for TIS. We measured adherence as the number of TIS therapy cycles completed during the year and categorized overall adherence as: low ≤ 2 cycles, medium >2 to <4 cycles, and high ≥ 4 cycles per year. Interquartile ranges (IQR) were created for health care utilization and logistic regression analysis of hospitalization risk was conducted by TIS adherence categories.Results: Among 804 individuals identified with CF and a prescription for TIS, only 7% (n = 54) received ≥ 4 cycles of TIS per year. High adherence with TIS was associated with a decreased risk of hospitalization when compared to individuals receiving ≤ 2 cycles (adjusted odds ratio 0.40; 95% confidence interval 0.19-0.84). High adherence with TIS was also associated with lower outpatient service costs (IQR: $2,159-$8444 vs. $2,410-$14,423) and higher outpatient prescription drug costs (IQR: $35,125-$60,969 vs. $10,353-$46,768).Conclusions: Use of TIS did not reflect recommended guidelines and may impact other health care utilization.

Original languageEnglish
Article number5
JournalBMC Pulmonary Medicine
Volume11
DOIs
StatePublished - Jan 20 2011

Fingerprint

Patient Acceptance of Health Care
Tobramycin
Inhalation
Cystic Fibrosis
Prescriptions
Hospitalization
Guidelines
Respiratory Therapy
Drug Costs
Prescription Drugs
Ambulatory Care
Outpatients
Logistic Models
Odds Ratio
Regression Analysis
Confidence Intervals
Delivery of Health Care

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Briesacher, B. A., Quittner, A., Saiman, L., Sacco, P., Fouayzi, H., & Quittell, L. M. (2011). Adherence with tobramycin inhaled solution and health care utilization. BMC Pulmonary Medicine, 11, [5]. https://doi.org/10.1186/1471-2466-11-5

Adherence with tobramycin inhaled solution and health care utilization. / Briesacher, Becky A.; Quittner, Alexandra; Saiman, Lisa; Sacco, Patricia; Fouayzi, Hassan; Quittell, Lynne M.

In: BMC Pulmonary Medicine, Vol. 11, 5, 20.01.2011.

Research output: Contribution to journalArticle

Briesacher, BA, Quittner, A, Saiman, L, Sacco, P, Fouayzi, H & Quittell, LM 2011, 'Adherence with tobramycin inhaled solution and health care utilization', BMC Pulmonary Medicine, vol. 11, 5. https://doi.org/10.1186/1471-2466-11-5
Briesacher BA, Quittner A, Saiman L, Sacco P, Fouayzi H, Quittell LM. Adherence with tobramycin inhaled solution and health care utilization. BMC Pulmonary Medicine. 2011 Jan 20;11. 5. https://doi.org/10.1186/1471-2466-11-5
Briesacher, Becky A. ; Quittner, Alexandra ; Saiman, Lisa ; Sacco, Patricia ; Fouayzi, Hassan ; Quittell, Lynne M. / Adherence with tobramycin inhaled solution and health care utilization. In: BMC Pulmonary Medicine. 2011 ; Vol. 11.
@article{2d057ebf1f854828b254498b59fa61f0,
title = "Adherence with tobramycin inhaled solution and health care utilization",
abstract = "Background: Adherence with tobramycin inhalation solution (TIS) during routine cystic fibrosis (CF) care may differ from recommended guidelines and affect health care utilization.Methods: We analyzed 2001-2006 healthcare claims data from 45 large employers. Study subjects had diagnoses of CF and at least 1 prescription for TIS. We measured adherence as the number of TIS therapy cycles completed during the year and categorized overall adherence as: low ≤ 2 cycles, medium >2 to <4 cycles, and high ≥ 4 cycles per year. Interquartile ranges (IQR) were created for health care utilization and logistic regression analysis of hospitalization risk was conducted by TIS adherence categories.Results: Among 804 individuals identified with CF and a prescription for TIS, only 7{\%} (n = 54) received ≥ 4 cycles of TIS per year. High adherence with TIS was associated with a decreased risk of hospitalization when compared to individuals receiving ≤ 2 cycles (adjusted odds ratio 0.40; 95{\%} confidence interval 0.19-0.84). High adherence with TIS was also associated with lower outpatient service costs (IQR: $2,159-$8444 vs. $2,410-$14,423) and higher outpatient prescription drug costs (IQR: $35,125-$60,969 vs. $10,353-$46,768).Conclusions: Use of TIS did not reflect recommended guidelines and may impact other health care utilization.",
author = "Briesacher, {Becky A.} and Alexandra Quittner and Lisa Saiman and Patricia Sacco and Hassan Fouayzi and Quittell, {Lynne M.}",
year = "2011",
month = "1",
day = "20",
doi = "10.1186/1471-2466-11-5",
language = "English",
volume = "11",
journal = "BMC Pulmonary Medicine",
issn = "1471-2466",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Adherence with tobramycin inhaled solution and health care utilization

AU - Briesacher, Becky A.

AU - Quittner, Alexandra

AU - Saiman, Lisa

AU - Sacco, Patricia

AU - Fouayzi, Hassan

AU - Quittell, Lynne M.

PY - 2011/1/20

Y1 - 2011/1/20

N2 - Background: Adherence with tobramycin inhalation solution (TIS) during routine cystic fibrosis (CF) care may differ from recommended guidelines and affect health care utilization.Methods: We analyzed 2001-2006 healthcare claims data from 45 large employers. Study subjects had diagnoses of CF and at least 1 prescription for TIS. We measured adherence as the number of TIS therapy cycles completed during the year and categorized overall adherence as: low ≤ 2 cycles, medium >2 to <4 cycles, and high ≥ 4 cycles per year. Interquartile ranges (IQR) were created for health care utilization and logistic regression analysis of hospitalization risk was conducted by TIS adherence categories.Results: Among 804 individuals identified with CF and a prescription for TIS, only 7% (n = 54) received ≥ 4 cycles of TIS per year. High adherence with TIS was associated with a decreased risk of hospitalization when compared to individuals receiving ≤ 2 cycles (adjusted odds ratio 0.40; 95% confidence interval 0.19-0.84). High adherence with TIS was also associated with lower outpatient service costs (IQR: $2,159-$8444 vs. $2,410-$14,423) and higher outpatient prescription drug costs (IQR: $35,125-$60,969 vs. $10,353-$46,768).Conclusions: Use of TIS did not reflect recommended guidelines and may impact other health care utilization.

AB - Background: Adherence with tobramycin inhalation solution (TIS) during routine cystic fibrosis (CF) care may differ from recommended guidelines and affect health care utilization.Methods: We analyzed 2001-2006 healthcare claims data from 45 large employers. Study subjects had diagnoses of CF and at least 1 prescription for TIS. We measured adherence as the number of TIS therapy cycles completed during the year and categorized overall adherence as: low ≤ 2 cycles, medium >2 to <4 cycles, and high ≥ 4 cycles per year. Interquartile ranges (IQR) were created for health care utilization and logistic regression analysis of hospitalization risk was conducted by TIS adherence categories.Results: Among 804 individuals identified with CF and a prescription for TIS, only 7% (n = 54) received ≥ 4 cycles of TIS per year. High adherence with TIS was associated with a decreased risk of hospitalization when compared to individuals receiving ≤ 2 cycles (adjusted odds ratio 0.40; 95% confidence interval 0.19-0.84). High adherence with TIS was also associated with lower outpatient service costs (IQR: $2,159-$8444 vs. $2,410-$14,423) and higher outpatient prescription drug costs (IQR: $35,125-$60,969 vs. $10,353-$46,768).Conclusions: Use of TIS did not reflect recommended guidelines and may impact other health care utilization.

UR - http://www.scopus.com/inward/record.url?scp=78651536177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651536177&partnerID=8YFLogxK

U2 - 10.1186/1471-2466-11-5

DO - 10.1186/1471-2466-11-5

M3 - Article

C2 - 21251275

AN - SCOPUS:78651536177

VL - 11

JO - BMC Pulmonary Medicine

JF - BMC Pulmonary Medicine

SN - 1471-2466

M1 - 5

ER -